UniProt Q8NBP7
Proprotein convertase subtilisin/kexin type 9 (Q8NBP7)
Proprotein convertase subtilisin/kexin type 9 (UniProt Q8NBP7), EC 3.4.21.-: 107 experimental structures on GenesisL1, 27 ligands bound, 96 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q8NBP7
- Protein
- Proprotein convertase subtilisin/kexin type 9
- EC
- 3.4.21.-
- Experimental structures
- 107
- Predicted models
- 0
- Ligands
- 27
- Pockets
- 96 · 23 records with a druggable one
Structures
107 records of Q8NBP7 in the MolNFT archive: 107 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2P4E | Crystal Structure of PCSK9 | x-ray diffraction | P, A | — | — |
| 2P4E | Crystal structure of PCSK9 | x-ray diffraction | P, A | — | — |
| 2QTW | The Crystal Structure of PCSK9 at 1.9 Angstroms Resolution Reveals structural homology to Resistin… | x-ray diffraction | A, B | — | — |
| 2QTW | The crystal structure of PCSK9 at 1.9 ångströms resolution reveals structural homology to resistin… | x-ray diffraction | A, B | — | — |
| 2W2M | Wt PCSK9-deltac bound to wt EGF-a of ldlr | x-ray diffraction | A, P | — | — |
| 2W2M | Wt PCSK9-deltac bound to wt EGF-a of ldlr | x-ray diffraction | A, P | — | — |
| 2W2N | WT PCSK9-deltaC bound to EGF-A H306Y mutant of LDLR | x-ray diffraction | A, P | — | — |
| 2W2N | Wt PCSK9-deltac bound to EGF-a H306Y mutant of ldlr | x-ray diffraction | A, P | — | — |
| 2W2O | PCSK9-deltaC D374Y mutant bound to WT EGF-A of LDLR | x-ray diffraction | A, P | — | — |
| 2W2O | PCSK9-deltac D374Y mutant bound to wt EGF-a of ldlr | x-ray diffraction | A, P | — | — |
| 2W2P | PCSK9-deltaC D374A mutant bound to WT EGF-A of LDLR | x-ray diffraction | A, P | — | — |
| 2W2P | PCSK9-deltac D374A mutant bound to wt EGF-a of ldlr | x-ray diffraction | A, P | — | — |
| 2W2Q | PCSK9-deltaC D374H mutant bound to WT EGF-A of LDLR | x-ray diffraction | A, P | — | — |
| 2W2Q | PCSK9-deltac D374H mutant bound to wt EGF-a of ldlr | x-ray diffraction | A, P | — | — |
| 2XTJ | The crystal structure of PCSK9 in complex with 1D05 Fab | x-ray diffraction | A, P | — | — |
| 2XTJ | The crystal structure of PCSK9 in complex with 1D05 Fab | x-ray diffraction | A, P | — | — |
| 3BPS | PCSK9:EGF-A complex | x-ray diffraction | P, A | — | — |
| 3BPS | PCSK9:EGF-a complex | x-ray diffraction | P, A | — | — |
| 3GCW | PCSK9:EGFA(H306Y) | x-ray diffraction | P, A | — | — |
| 3GCW | PCSK9:EGFA(H306Y) | x-ray diffraction | P, A | — | — |
| 3GCX | PCSK9:EGFA (pH 7.4) | x-ray diffraction | P, A | — | — |
| 3GCX | PCSK9:EGFA (pH 7.4) | x-ray diffraction | P, A | — | — |
| 3H42 | Crystal structure of PCSK9 in complex with Fab from LDLR competitive antibody | x-ray diffraction | A, B | — | — |
| 3H42 | Crystal structure of PCSK9 in complex with Fab from ldlr competitive antibody | x-ray diffraction | A, B | — | — |
| 3M0C | The X-ray Crystal Structure of PCSK9 in Complex with the LDL receptor | x-ray diffraction | A, B | — | — |
| 3M0C | The X-ray crystal structure of PCSK9 in complex with the LDL receptor | x-ray diffraction | A, B | — | — |
| 3P5B | The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation | x-ray diffraction | P, A | — | — |
| 3P5B | The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation | x-ray diffraction | P, A | — | — |
| 3P5C | The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation | x-ray diffraction | P, A | — | — |
| 3P5C | The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation | x-ray diffraction | P, A | — | — |
| 3SQO | PCSK9 J16 Fab complex | x-ray diffraction | A, P | — | — |
| 3SQO | PCSK9 J16 Fab complex | x-ray diffraction | A, P | — | — |
| 4K8R | An Antibody Against the C-terminal Domain of PCSK9 lowers LDL Cholesterol Levels in vivo | x-ray diffraction | A, B | — | — |
| 4K8R | An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo | x-ray diffraction | A, B | — | — |
| 4NE9 | PCSK9 in complex with LDLR peptide | x-ray diffraction | A, B, C, P | — | — |
| 4NE9 | PCSK9 in complex with ldlr peptide | x-ray diffraction | A, B, C, P | — | — |
| 4NMX | PCSK9(deltaCRD) in complex with phage-derived inhibitory peptide 2-8 | x-ray diffraction | A, B | — | — |
| 4NMX | PCSK9(DELTACRD) in complex with phage-derived inhibitory peptide 2-8 | x-ray diffraction | A, B | — | — |
| 4OV6 | Crystal structure of PCSK9(53-451) with Adnectin | x-ray diffraction | A, B, D, E | — | — |
| 4OV6 | Crystal structure of PCSK9(53-451) with adnectin | x-ray diffraction | A, B, D, E | — | — |
| 5OCA | PCSK9:Fab Complex with Dextran Sulfate | x-ray diffraction | A, B | TWD, TWA, NA | 6 (best 0.77) |
| 5OCA | PCSK9:FAB complex with dextran sulfate | x-ray diffraction | A, B | TWD, TWA, NA | — |
| 5VL7 | PCSK9 complex with Fab33 | x-ray diffraction | A, B | — | 3 (best 0.75) |
| 5VL7 | PCSK9 complex with FAB33 | x-ray diffraction | A, B | — | — |
| 5VLA | Short PCSK9 delta-P' complex with Fusion2 peptide | x-ray diffraction | A | CA | 2 (best 0.25) |
| 5VLA | Short PCSK9 delta-P' complex with FUSION2 peptide | x-ray diffraction | A | CA | — |
| 5VLH | Short PCSK9 delta-P' complex with peptide Pep1 | x-ray diffraction | A | CA | — |
| 5VLH | Short PCSK9 delta-P' complex with peptide PEP1 | x-ray diffraction | A | CA | — |
| 5VLK | Short PCSK9 delta-P' complex with shrunken peptide bearing homo-Arginine | x-ray diffraction | A | CA | 1 (best 0.24) |
| 5VLK | Short PCSK9 delta-P' complex with shrunken peptide bearing homo- arginine | x-ray diffraction | A | CA | — |
| 5VLL | Short PCSK9 delta-P' complex with peptide Pep3 | x-ray diffraction | A | CA | 2 (best 0.27) |
| 5VLL | Short PCSK9 delta-P' complex with peptide PEP3 | x-ray diffraction | A | CA | — |
| 5VLP | PCSK9 complex with LDLR antagonist peptide and Fab7G7 | x-ray diffraction | A | NA | 5 (best 0.73) |
| 5VLP | PCSK9 complex with ldlr antagonist peptide and FAB7G7 | x-ray diffraction | A | ACE, NA | — |
| 6E4Y | Anti-PCSK9 fab 6E2 bound to the N-terminal peptide from PCSK9, unmodified | x-ray diffraction | P | ZN, CL | 2 (best 0.63) |
| 6E4Y | Anti-PCSK9 Fab 6E2 bound to the N-terminal peptide from PCSK9, unmodified | x-ray diffraction | P | ZN, CL | — |
| 6E4Z | Anti-PCSK9 fab 6E2 bound to the modified N-terminal peptide from PCSK9 | x-ray diffraction | P | ZN | 2 (best 0.62) |
| 6E4Z | Anti-PCSK9 Fab 6E2 bound to the modified N-terminal peptide from PCSK9 | x-ray diffraction | P | ZN | — |
| 6MV5 | Anti-PCSK9 fab 6E2 bound to the N-terminal peptide from PCSK9 (E32K) | x-ray diffraction | P | ZN, CL, SO4 | — |
| 6MV5 | Anti-PCSK9 Fab 6E2 bound to the N-terminal peptide from PCSK9 (E32K) | x-ray diffraction | P | ACE, ZN, CL, SO4 | — |
47 records more on the page itself.
Ligands
- CA · Calcium ion · in 21 records
- ZN · Zinc ion · in 6 records
- 89N · (2E)-but-2-ene-1,4-diol · in 4 records
- ACE · Acetyl group · in 4 records
- CL · Chloride ion · in 4 records
- NA · Sodium ion · in 4 records
- SO4 · Sulfate ion · in 4 records
- B74 · (3-methylphenyl)methanol · in 3 records
- 063 · 4'-{[(1R)-6-{2-[2-({N~5~-[N,N'-bis(tert-butoxycarbonyl)carbamimidoyl]-N~2~-(tert-butoxycarbonyl)-L-ornithyl}amino)ethoxy]ethoxy}-1-methyl-1-{2-oxo-2-[(1,3-thiazol-2-yl)amino]ethyl}-1,2, 3,4-tetrahydroisoquinolin-7-yl]oxy}-2'-fluoro[1,1'-biphenyl]-4-carboxylic acid · in 2 records
- DHL · 2-amino-ethanethiol · in 2 records
- FUC · alpha-L-fucopyranose · in 2 records
- MPT · Beta-mercaptopropionic acid · in 2 records
- MVM · N-(3-chloropyridin-2-yl)-N-[(3R)-piperidin-3-yl]-4-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)benzamide · in 2 records
- NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · in 2 records
- PQG · Cis-1-amino-4-phenylcyclohexane-1-carboxylic acid · in 2 records
- PV7 · 4-{[(1R)-6-methoxy-1-methyl-1-{2-oxo-2-[(1,3-thiazol-2-yl)amino]ethyl}-1,2,3,4-tetrahydroisoquinolin-7-yl]oxy}benzoic acid · in 2 records
- PVJ · 2-fluoro-4-{[(1R)-1-methyl-6-{[(2S)-oxan-2-yl]methoxy}-1-{2-oxo-2-[(1,3-thiazol-2-yl)amino]ethyl}-1,2,3,4-tetrahydroisoquinolin-7-yl]oxy}benzoic acid · in 2 records
- PVM · 2-fluoro-4-{[(1R)-6-(2-{4-[1-(4-methoxyphenyl)-5-methyl-6-oxo-1,6-dihydropyridazin-3-yl]-1H-1,2,3-triazol-1-yl}ethoxy)-1-methyl-1-{2-oxo-2-[(1,3-thiazol-2-yl)amino]ethyl}-1,2,3,4-tetrahydroisoquinolin-7-yl]oxy}benzoic acid · in 2 records
- PVV · 2-[(1R)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]-N-(1,3-thiazol-2-yl) acetamide · in 2 records
- TWA · 2,3,4-tri-O-sulfo-beta-D-altropyranose · in 2 records
- TWD · 2,3-di-O-sulfo-alpha-L-glucopyranose · in 2 records
- WCM · (2S)-2-amino-3-(biphenyl-4-yl)-N-methyl-N-[(2S)-1-oxopropan-2-yl]propanamide (non-preferred name) · in 2 records
- NEH · Ethanamine · in 1 record
- NH2 · Amino group · in 1 record
- PUV · 2-fluoro-4-{[(1R)-6-methoxy-1-methyl-1-{2-oxo-2-[(1,3-thiazol-2-yl)amino]ethyl}-1,2,3,4-tetrahydroisoquinolin-7-yl]oxy}benzoic acid · in 1 record
- V7M · 1-fluoro-3,5-dimethylbenzene · in 1 record
- V7S · 1,3-bis[(methylsulfanyl)methyl]benzene · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.